- shut down
Sirtris and its
development candidates were
absorbed into GSK,
where research and
development continued. At that time, GSK/
Sirtris' lead candidate...
-
Sinclair founded Sirtris Pharmaceuticals along with
Andrew Perlman,
Christoph Westphal,
Richard Aldrich,
Richard Pops, and Paul Schimmel.
Sirtris was focused...
- to
resign from the nonprofit. GSK/
Sirtris terminated development of SRT501 in late 2010. In 2013 GSK shut down
Sirtris and its
development candidates were...
-
professor David Sinclair co-founded
Sirtris Pharmaceuticals, the
initial product of
which was a
resveratrol formulation.
Sirtris was
purchased and made a subsidiary...
- SRT-2104 is an
experimental drug that was
studied by
Sirtris Pharmaceuticals as a small-molecule
activator of the
sirtuin subtype SIRT1. The compound...
-
regular polypeptide substrates, with an
influence of the
substrate sequence.
Sirtris Pharmaceuticals, Sinclair's company, was
purchased by
GlaxoSmithKline (GSK)...
- SRT-3025 is an
experimental drug that was
studied by
Sirtris Pharmaceuticals as a small-molecule
activator of the
sirtuin subtype SIRT1. It has been investigated...
- SRT-1720 is an
experimental drug that was
studied by
Sirtris Pharmaceuticals intended as a small-molecule
activator of the
sirtuin subtype SIRT1. The...
- 2008, she
became vice
president of
corporate development at
Sirtris Pharmaceuticals.
Sirtris was
purchased and made a
subsidiary of
GlaxoSmithKline in 2008...
- Network.
Retrieved 2021-02-19. "
Sirtris launches IPO". www.bizjournals.com.
Retrieved 2021-02-22. "GSK buys
Sirtris for $720M". FierceBiotech. 23 April...
